China Healthcare:Further execution in 19provinces

类别:行业研究 机构:国信证券(香港)金融控股有限公司 研究员:Jason Siu 日期:2017-10-12

On 20 Sept 2017, Economics Information Daily (经济参考报) reported that fouradditional provinces, namely Jiangxi, Yunnan, Gansu and Shanxi, had included 36high-priced medicines into their provincial reimbursement drug list (RDL). Thesedrug names are the same as those shortlisted by the national government on 19July. Including these four provinces, it should now have over 19 provinces to addthese 36 drugs into their RDL.

    The article highlighted that, as imported drugs can now be included into RDL at thebigger expense of selling prices, this makes the cheaper local-made medicines tobe less competitive in the market. In addition, the national government will try toimplement this bigger price cut mechanism on high-priced medicines in exchangefor their volume jump in most provinces. Coupled with good surveillance of drugcost spending, Chinese government aims to curb the over-usage of these highpriceddrugs, including monoclonal antibodies.

    The same source also cited that, with the drug cost reimbursement amount fixedby the government post negotiation, it would be unlikely to see bigger selling pricefluctuations to hospitals for these high-priced medicines. Whereby these drugs areusually (1) to treat critical and rare diseases such as cancers; and (2) hard toproduce with good barriers of entry.

    As we flagged in our 12 Sept 2017 note, we see these drugs with clinicalimportance would likely have their sales volume rebound (in particular to foreigndrugs), at the expense of their selling prices, similar to the case with GSK’sTenofovir Disoproxil Fumarate (Viread?). Consistent with national governmentpolicy, it aims to provide Chinese masses accessible to cheaper quality medicinewith good efficacies. We expect this will increase the likelihood for many provincesto introduce further price cut on domestic drugs for critical illness, such as anticancerand stroke medicines.

    Stock impact: This will dampen the sentiment of local drug-maker sector in theshort-term, despite of potential sales volume rebound for these import drugs fromsacrificing their selling prices. Same as we mentioned, we do not surprise to seefurther tough policy (such as price cut) on domestic high-priced drugs such aschemical drugs and monoclonal antibodies for anti-cancer therapy. Aside fromChina Medical System’s (867.HK, NR) XinHuoSu (新活素?; Nesiritide?), we see thismay also affect HK-listed CSPC (1093.HK, NR)’s future pricing on its Bortezomib forinjection (硼替佐米) as a first-to-market generic drug, which is currently on thathigh-priced drug list. Note that, CSPC has applied for production approval fromCFDA, likely to be on sales in the next 12 to 16 months.



金河生物 持有 8.12 研报
数据港 买入 -- 研报
中科曙光 买入 -- 研报
用友网络 持有 -- 研报
光环新网 买入 -- 研报
锦富技术 买入 -- 研报
广联达 持有 -- 研报
博世科 持有 -- 研报
蒙草生态 持有 -- 研报
铁汉生态 持有 -- 研报
东方园林 持有 -- 研报


金河生物 0 0.87 研报
中科曙光 0 0 研报
光环新网 0 0 研报
数据港 0 0 研报
锦富技术 0.58 0.69 研报
用友网络 0.66 0.70 研报
广联达 1.09 0.95 研报
博世科 0 0 研报
蒙草生态 0 0.78 研报
东方园林 3.19 2.67 研报
铁汉生态 1.56 1.10 研报


清新环境 36 持有 买入
山西汾酒 31 持有 持有
中国国旅 28 持有 买入
中兴通讯 27 持有 买入
聚光科技 27 持有 持有
恒瑞医药 26 持有 持有
锦江股份 26 持有 持有
万科A 26 持有 持有
国轩高科 26 持有 持有
太阳纸业 26 持有 中性
中青旅 25 持有 持有
伊利股份 25 持有 持有
汇川技术 25 持有 买入
招商银行 24 持有 买入
黄山旅游 24 持有 买入
洋河股份 24 持有 持有
登海种业 23 持有 中性


电子信息 653 106 183
生物制药 477 66 216
化工行业 444 71 183
机械行业 433 86 116
食品行业 386 34 139
建筑建材 366 49 162
汽车制造 350 42 94
酿酒行业 336 19 75
环保行业 335 22 65
酒店旅游 331 27 168
房地产 323 55 104
交通运输 318 43 134
金融行业 318 30 124
农林牧渔 301 36 111
煤炭行业 278 31 47
电子器件 270 69 76
服装鞋类 248 31 103